
Min Zhang,1,2,* Hao Sun,3,* Jin Zeng,1 Lixian Li,1 Qiaoqiao Li,1,2 Tiantian Tang,1 Xiaoxiao Wang,1,2 Wanyi Chen1 1Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, 400030, People’s Republic of China; 2State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, 210023, People’s Republic of China; 3Department of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing, 400030, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiaoxiao Wang, Email wangxiaoxiao891021@163.com Wanyi Chen, Email chenwanyi@cqu.edu.cnPurpose: Imatinib is a standard therapy for gastrointestinal stromal tumors (GISTs) but exhibits substantial interindividual pharmacokinetic variability, highlighting the need for individualized dose optimization. Given the uncertain transferability of published imatinib population pharmacokinetic (PopPK) models, this study aimed to evaluate their external predictive performance using real-world therapeutic drug monitoring (TDM) data and develop a center-specific PopPK model to support individualized dosing.Patients and Methods: Published PopPK models of imatinib in patients with GISTs were identified through a literature review. Real-world TDM data from adult patients with GISTs receiving imatinib were used for external evaluation with prediction-based diagnostics and visual predictive checks (VPC). A center-specific PopPK model was subsequently developed using NONMEM, and Monte Carlo simulations were performed to evaluate individualized dosing strategies.Results: Six published imatinib PopPK models were identified, of which five were successfully reconstructed and externally evaluated using data from 150 patients with GISTs. None fully met the prespecified criteria for population predictive performance. The final center-specific model was a one-compartment model with first-order absorption and first-order elimination. The typical apparent clearance (CL/F) was 9.77 L/h. Body weight and ABCG2 rs2231142 genotype were retained as covariates on CL/F, with a more pronounced estimated effect observed for the GT genotype. The final model met the predefined acceptance criteria for both population and individual predictions. Simulations suggested that lower body weight and the GT genotype were associated with higher steady-state trough concentrations (Ctrough, ss), whereas the effect of the TT genotype was less certain. At the same dose, higher body weight and the GG genotype were generally associated with lower simulated exposure.Conclusion: Published imatinib PopPK models showed limited predictive performance in the present GIST population. The center-specific model characterized interindividual variability in imatinib concentrations, with body weight and ABCG2 rs2231142 genotype included as covariates on CL/F, although the TT genotype effect remained uncertain. Model-based dosing simulations are exploratory and require independent external validation and prospective studies to establish their clinical utility.Graphical Abstract: A) Clinical problem infographic column labeled 1 Clinical problem. Text reads, GISTs gastrointestinal stromal tumors. Text reads, Imatinib tyrosine kinase inhibitor. Three statements read, Imatinib shows substantial PK variability. Conventional TDM may delay dose optimization. Need for model-informed precision dosing MIPD. Visuals include a human body icon with a highlighted stomach area, a capsule icon and three circular icons aligned with the three statements. B) External evaluation infographic column labeled 2 External evaluation. Text reads, 6 published imatinib PopPK models identified. Text reads, Real-world TDM data: 150 adult patients with GISTs. Text reads, Published imatinib PopPK models Reconstruction. Text reads, Externally evaluated. Text reads, Published models showed limited transferability. A table titled, Model performance population level, has columns, Model, MDPE percent, MAPE percent, F20 percent, F30 percent. Row reads, Published models BestModel 3, minus 14.65, 30.77, 35.59, 49.41. Row reads, Final model Center-specific, 0.46, 28.48, 36.52, 59.22. Statement below reads, No published model fully met prespecified population predictive criteria. Visuals include stacked document and building icons near the first two statements and small icons next to the reconstruction, evaluation and transferability statements. C) Center-specific PopPK model infographic column labeled 3 Center-specific PopPK model. Equation text reads, CL slash F L slash h equals 9.77 times left parenthesis WT over 60 right parenthesis to the power of 0.942 times 0.886 TT times 0.775 GT times e to the power of eta subscript CL end superscript. Text reads, V slash F L equals 229. Paragraph reads, where WT represents body weight; GT and TT are indicator variables coded as 1 for the corresponding genotype and 0 otherwise, with both set to 0 for the GG genotype. The estimated TT genotype effect remains uncertain. A table labeled, Interindividual variability, Estimate, includes, IIV CL slash F, 37.4 percent. A table labeled, Residual unexplained variability, Estimate, includes, Proportional residual error, 0.282. Statement reads, Center-specific model improved population-level predictive performance. Visuals include a rising bar chart icon near the final statement. D) Exploratory dosing simulation infographic column labeled 4 Exploratory dosing simulation. Statements read, At the same dose, simulated concentrations were generally higher in patients with lower body weight. Statement reads, Simulated exposure and target attainment may vary by dose, body weight and ABCG2 genotype. Statement reads, 6 models identified; 5 reconstructed and externally evaluated. Warning statement reads, Simulated dosing scenarios are exploratory and require prospective validation. Visuals include a target icon near the first statement, a capsule icon near the second statement, small person and DNA icons near the third statement and a warning triangle icon near the warning statement. Bottom banner text reads, Conclusion: Published imatinib PopPK models showed limited population-level predictive performance under the conditions of this external evaluation. The center-specific model provided an exploratory framework for assessing imatinib exposure across patient subgroups.A four-step infographic on imatinib PopPK models, external evaluation, center-specific modeling and simulation.Keywords: gastrointestinal stromal tumors, imatinib, population pharmacokinetics, therapeutic drug monitoring, individualized dosing
Wo Tian, Bo Wang Department of Spine Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, 116011, People’s Republic of ChinaCorrespondence: Bo Wang, Department of Spine Surgery, The First Affiliated Hospital of Dalian Medical University, No. 222, Zhongshan Road, Xigang District, Dalian, Liaoning, 116011, People’s Republic of China, Email tianwo11111@163.com
Xinyu Zhang,1–5 Yang Wang1–5 1Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, People’s Republic of China; 2National Clinical Research Center for Obstetrics and Gynecology, Peking University Third Hospital, Beijing, People’s Republic of China; 3Key Laboratory of Assisted Reproduction, Peking University, Ministry of Education, Beijing, People’s Republic of China; 4Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, People’s Republic of China; 5State Key Laboratory of Female Fertility Promotion, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, People’s Republic of ChinaCorrespondence: Yang Wang, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, No. 49, North Garden Road, Haidian District, Beijing, People’s Republic of China, Email wangbearyang@163.com
Meng Liu,1,* Haoxin Fu,2,* Xiaohai Chen,2 Zhenwei Yu,3 Ren-Ai Xu,2 Yingying Wang2 1Department of Clinical Pharmacy, Lu’an Hospital of Traditional Chinese Medicine, Lu’an, 237006, People’s Republic of China; 2Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People’s Republic of China; 3Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, People’s Republic of China*The work has been contributed by these authors equallyCorrespondence: Yingying Wang, Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People’s Republic of China, Tel +86 15906465513, Email Wangyingying@wmu.edu.cn Ren-Ai Xu, Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People’s Republic of China, Tel +86 15088554595, Email ysxurenai@hotmail.comBackground: Linezolid therapy may be complicated by hematologic toxicity and lactic acidosis. Its major metabolites, PNU-142300 and PNU-142586, can accumulate with impaired renal function, but their contribution to adverse outcomes remains uncertain. Renal function and baseline laboratory abnormalities may confound concentration-outcome associations, highlighting the need to assess whether metabolite measurements provide additional information beyond routinely available clinical indicators.Objective: To assess the associations of linezolid, PNU-142300, and PNU-142586 trough concentrations (Cmin) with renal function and adverse outcomes during treatment, and their exploratory discriminative performance.Methods: A retrospective observational study was conducted in patients who had received linezolid and in whom Cmin of linezolid and its metabolites (PNU-142300 and PNU-142586) was available. An ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was used to quantify these compounds in human serum. Linear regression was performed to evaluate the association between Cmin of linezolid and its metabolites. The correlation of linezolid, PNU-142300, and PNU-142586 with eCrCl were analyzed by Spearman rank correlation coefficient. Cmin of linezolid and its metabolites were compared with different linezolid-related toxicity groups. The receiver operating characteristic (ROC) curve was used to analyze the associative values of linezolid and its metabolites for anemia, thrombocytopenia, and lactic acidosis, and the area under the curve (AUC) was calculated.Results: Thrombocytopenia, anemia, and lactic acidosis occurred in 44 (17.5%), 53 (21.0%), and 56 (22.2%) patients, respectively. All analytes were inversely correlated with eCrCl (linezolid, r=− 0.423; PNU-142300, r=− 0.715; PNU-142586, r=− 0.683; all P< 0.001). After adjustment, no analyte was significantly associated with thrombocytopenia, and neither metabolite was significantly associated with anemia. Linezolid showed an unexpected inverse association with anemia (adjusted OR, 0.934; P=0.030). Higher linezolid, PNU-142300, and PNU-142586 concentrations were associated with lactic acidosis (adjusted ORs, 1.073, 1.027, and 1.031; P=0.004, 0.014, and 0.047, respectively). Individual-analyte AUCs ranged from 0.641 to 0.680. Adding each analyte to baseline lactate, eCrCl, and age increased the apparent AUC from 0.675 to 0.707– 0.720, without statistically significant improvement.Conclusion: Concentration measurements should complement baseline and serial laboratory assessments and renal-function evaluation. The clinical value of additional metabolite monitoring remains unestablished. Prospective validation is required before routine metabolite-specific TDM can be recommended.Keywords: linezolid, metabolites, UPLC-MS/MS, toxicity, TDM
Cheng P, Chen K, Xia Y, et al. Drug Des Devel Ther. 2014;8:1277–1286. https://doi.org/10.2147/DDDT.S66573 We, the Editors and Publisher of the journal Drug Design, Development and Therapy, have retracted the published article. After publication, concerns have been raised by a third party in 2025 about the integrity of the data in Figures 2, 4, and 5 of the article. Further investigation conducted by the Journal and Publisher confirmed the following: Unusual similarities present in the image panels representative of different treatment conditions in Figure 2C Unusual similarities between images representative of different conditions between Figure 4C, and 5B. Unexpected similarities between the Western blots representing different experimental conditions in Figure 2B and 5A. Unexpected similarities between images in Figures 2C, 4C, 4D and 5Bof the article with the authors’ previous publication that are representative of different treatment conditions: Shen, Miao, Lu, Jie, Dai, Weiqi, Wang, Fan, Xu, Ling, Chen, Kan, He, Lei, Cheng, Ping, Zhang, Yan, Wang, Chengfen, Wu, Dong, Yang, Jing, Zhu, Rong, Zhang, Huawei, Zhou, Yinqun, Guo, Chuanyong, Ethyl Pyruvate Ameliorates Hepatic Ischemia-Reperfusion Injury by Inhibiting Intrinsic Pathway of Apoptosis and Autophagy, Mediators of Inflammation, 2013, 461536, 12 pages, 2013. https://doi.org/10.1155/2013/461536 Unexpected similarities between a western blot in Figure 5A of the article with the authors’ previous publication which is representative of different samples and proteins: Cheng, Ping, Wang, Fan, Chen, Kan, Shen, Miao, Dai, Weiqi, Xu, Ling, Zhang, Yan, Wang, Chengfen, Li, Jingjing, Yang, Jing, Zhu, Rong, Zhang, Huawei, Zheng, Yuanyuan, Lu, Jie, Zhou, Yingqun, Guo, Chuanyong, Hydrogen Sulfide Ameliorates Ischemia/Reperfusion-Induced Hepatitis by Inhibiting Apoptosis and Autophagy Pathways, Mediators of Inflammation, 2014, 935251, 16 pages, 2014. https://doi.org/10.1155/2014/935251 When approached for an explanation, the authors did not respond to the queries raised by the Journal and Publisher. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The corresponding author listed in this publication has been informed. We have been informed in our decision-making by our editorial policies and the COPE guidelines. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.